Serum Prolactin Levels in Dermatological Diseases: A Case-Control Study

    April 2015 in “ Journal of Dermatology and Dermatologic Surgery ”
    Nadia Abdalhafid Elsherif, Abdalla I. El‐Sherif, Salwa A. El-Dibany
    Image of study
    TLDR People with certain skin diseases have higher levels of the hormone prolactin in their blood.
    In a case-control study with 100 subjects, researchers found that serum prolactin (PRL) levels were significantly higher in 75 patients with psoriasis, vitiligo, and alopecia areata compared to 25 healthy controls. The mean serum PRL levels were 21.8 ± 11.5 ng/ml in alopecia areata patients, 16.9 ± 6.8 ng/ml in those with psoriasis, and 16.6 ± 8.0 ng/ml in vitiligo patients. There was also a significant correlation between serum PRL levels and disease severity in alopecia areata and psoriasis patients, but not in those with vitiligo. The study suggested that prolactin might contribute to the pathogenesis of these dermatological diseases and could be a marker for disease activity in psoriasis and alopecia areata.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  37 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

      community hmi115 is coming. Prepare yourselves for what's coming

      in Technology  108 upvotes 1 year ago
      The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  120 upvotes 1 year ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

    Related Research

    1 / 1 results